Saliva-based diagnostics for the early detection of liver disease and head & neck cancer.

SALCheck™ is a diagnostic platform built around saliva as its biological medium, with individual products developed for specific clinical indications. Each indication brings its own competitive landscape (eg blood-based scores and elastography in liver fibrosis, biopsy and clinical inspection in oral and oropharyngeal cancer), and SALCheck™ competes against those incumbents on a different axis. Rather than trying to outperform existing tests on raw analytical accuracy, SALCheck™ is designed to reach patients those tests miss. Today's screening pathways depend on patients reaching specialist care, dedicated equipment, or trained interpretation - barriers that prevent many from accessing care. SALCheck™ removes these barriers by collecting a saliva sample in seconds and delivering a result at point of care.

Saliva contains validated diagnostic biomarkers across hepatic, oncologic, metabolic, and inflammatory pathways - a remarkably rich and accessible biological matrix. What has historically limited its use in clinical diagnostics is analytical sensitivity. Biomarker concentrations are typically lower in saliva than in blood, which requires purpose-built assay chemistry to measure reliably. The SALCheck™ platform addresses this through diagnostic architecture engineered specifically for low-abundance salivary biomarker detection. Saliva is not a workaround for blood - it is a deliberately chosen matrix that allows clinical-grade screening to reach the settings where patients are most likely to be seen, without phlebotomy, scheduling, or specialist infrastructure.

Calaris is in active development through early 2027, working with a UK-based contract development and manufacturing partner for its flagship product, SALCheck™ Liver. The development plan progresses through prototype build, analytical validation, and clinical performance studies in advance of planned regulatory submissions across multiple international jurisdictions including the US, UK, Canada, and Australia. Calaris is not currently selling products.

Calaris's flagship, SALCheck™ Liver, is being developed as a novel in vitro diagnostic intended for use at point of care. The regulatory strategy reflects that intent: designed for clearance in multiple jurisdictions with deployment in primary care and community settings as the commercial focus. More detailed regulatory information will be shared as submissions progress.

Calaris holds exclusive global licenses to the underlying biomarker technology, developed by a research team at an Australian academic partner institution. Calaris also develops proprietary algorithms and reader technology on top of the licensed biomarker platform.

Calaris is open to clinical, partnership, and research conversations. Clinicians interested in the science can reach out through our contact form. Partnership inquiries, including pharma collaboration, distribution, and translational research, are handled the same way. Please indicate the category of inquiry when you reach out and we will route to the right person.